

ANNUAL REPORT

2024

Canadian Dupuytren Society | dupuytrenCanada.ca

CANADIAN
DUPUYTREN
SOCIETY






OUR MISSION

To promote health by leading the fight against Dupuytren's disease (DD) in Canada by helping people with DD live a healthy and functional life while we work to find a cure.

To promote health by finding the best available care and treatment for people suffering from DD and the related Ledderhose disease (LD).

To advance education related to DD by providing latest services and educational material to the public. To promote health by encouraging the search for the underlying causes and subsequent cures for DD and LD.



THE YEAR IN REVIEW

The year 2024 was marked by a repositioning and refocusing on our original mission: to help people with Dupuytren Disease find reliable information about the disease and its treatments, and to encourage communication and collaboration between specialists. We have also reduced our focus on research.

We have expanded our website's interactive tool to enable users to find doctors and health specialists, as well as physiotherapists and occupational therapists who treat hand disorders.

The Society has created a survey to understand our audience and their needs for information and other forms of support. Detailed results are expected in 2025. The survey has also been used to contact potential volunteers who could help in many areas, whether administrative or directly related to our charitable programs.

The conflict of interest policy for the Medical Advisory Board has been implemented and extended to the directors to provide a declaration process guaranteeing the credibility of the Company and the reliability of the information published on its website.



Figure 1



THE YEAR IN DETAIL



PATIENT'S SURVEY

The Society has completed the development and distribution of an audience survey to understand how patients in Canada are managing their disease, the key issues and challenges they face, and the support they would like to receive from the Society. Preliminary results show that patients are looking for healthcare professionals who are knowledgeable about all aspects of the disease and all treatment options. They also show a strong need for information about new treatments and ongoing research. More detailed results will be available in 2025 and will enable us to target the actions to be prioritized in 2025 to better meet their needs.



JOINT INNOVATION GRANT WITH THE ARTHRITIS SOCIETY

The joint Arthritis Society of Canada/Canadian Dupuytren Society Stimulating Research grant program saw no research projects qualifying for the grant in 2024. The Society has decided to continue its participation to the program for 2025.

CONFLICT OF INTEREST POLICY

The conflict of interest policy for members of the Medical Advisory Committee and the Board of Directors was finalized during the year. The Canadian Dupuytren Society has adopted a policy for managing real, perceived or potential conflicts of interest, in order to prevent and avoid the presence of commercial bias in discussions and consultations of its Medical Advisory Board, as well as in the company's strategic or management decisions.



EMAIL ENQUIRIES

Over the past year, the number of online requests for information about Dupuytren's disease and related conditions has remained constant. The requests and needs expressed by respondents related to this pathology show that the vast majority of requests are for information about Dupuytren's disease, but some people are affected by more than one condition.

The geographic distribution shows a concentration of requests in Ontario and Quebec, which may lead to reflection on the efforts of the Canadian Dupuytren Society to develop resources and services, as well as the level of penetration of these resources in Canada.

The questions asked highlight the strong interest of people affected by Dupuytren's disease in non-invasive treatments and alternatives to surgery. The demand for information on collagenase and radiation therapy is particularly high. The requesters are mainly looking for specialists with in-depth knowledge of all the treatments available for this pathology. Other specific requests include information on:

- **early and preventive treatments ;**
- **specific treatments for Leddherhose disease;**
- **alternative treatments to avoid surgery.**



FINANCIAL INFORMATION

The Canadian Dupuytren Society (“CDS”) financial position at year end remains strong with cash and allocated research reserves exceeding \$42,000. For the year ended December 31, 2024, total revenues generated amounted to more than \$10,500 and expenditures amounted to approximately \$10,800. The majority of expenditures, totaling \$9,229 related to the continued development and expansion of the CDS website and the support of other charitable programs. Operational costs for general and administrative incurred in the year remain low and totaled approximately \$1,650.

FORECAST

For 2025, we are budgeting \$14,000 of revenue and are projected to incur approximately \$14,000 in expenditures. The majority of our budgeted expenditures, approximately \$12,550, will be incurred and relate to our charitable program costs.

STATEMENTS OF FINANCIAL POSITION

	December 31, 2024	December 31, 2023
Assets		
Current Assets		
Cash	32 772,51 \$	34 765,74 \$
Allocated Research Funds	10 000,00 \$	10 000,00 \$
Accounts Receivable	2 775,62 \$	60,00 \$
GST/QST ITC's	1 432,95 \$	2 479,95 \$
Total Assets	46 981,08 \$	47 305,69 \$
Liabilities & Equity		
Liabilities		
Accounts Payable	746,40 \$	731,30 \$
Equity	46 234,68 \$	46 574,39 \$
Total Liabilities & Equity	46 981,08 \$	47 305,69 \$

STATEMENTS OF OPERATION

	December 31, 2024	December 31, 2023
Revenue		
Donations	10 317,50 \$	17 841,36 \$
Membership Fees	220,00 \$	160,00 \$
	10 537,50 \$	18 001,36 \$
Operating Expenditures		
National Communication Charitable Programs	4 963,65 \$	3 473,74 \$
Insurance	795,80 \$	795,80 \$
Business Licenses & Membership	969,15 \$	885,30 \$
Donation Expenses & Bank Charges	302,06 \$	644,98 \$
Administration and Processing	1 346,55 \$	847,91 \$
Technical Conference Expense	2 500,00 \$	0,00 \$
Office	0,00 \$	120,00 \$
	10 877,21 \$	6 767,73 \$
Excess (Deficit) of Revenue over Expenditures	-339,71 \$	11 233,63 \$

